Treatment of advanced hepatocellular carcinoma with long-acting octreotide: A phase III multicentre, randomised, double blind placebo-controlled study
European Journal of Cancer2009Vol. 45(10), pp. 1788–1797
Citations Over TimeTop 10% of 2009 papers
Jean‐Claude Barbare, Olivier Bouché, Franck Bonnetain, Laëtitia Dahan, Catherine Lombard‐Bohas, Roger Faroux, Jean‐Luc Raoul, Stéphane Cattan, Alain Lemoine, Jean‐Frédéric Blanc, Jean–Pierre Bronowicki, Jean‐Pierre Zarski, Sophie Cazorla, D. Gargot, Thierry Thévenot, Emmanuel Diaz, Anne Bastie, Thomas Aparicio, Laurent Bedenne
Related Papers
- → Effect of Octreotide LAR Dose and Weight on Octreotide Blood Levels in Patients With Neuroendocrine Tumors(2005)47 cited
- → Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients(2008)32 cited
- Octreotide inhibits pancreatic exocrine secretion and prevents pancreatoenterostomy leakage.(2001)
- Clinical Studies of Octreotide Treatment of Acute Pancreatitis(2012)
- Role of Prophylactic Octreotide in Pancreaticoduodenectomy: A Single Centre Comparative Study in 456 Whipple's Patients(2016)